These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30537942)

  • 1. Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.
    Merz PR; Röckel N; Ballikaya S; Auffarth GU; Schmack I
    BMC Ophthalmol; 2018 Dec; 18(1):316. PubMed ID: 30537942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The influence of VEGF inhibitors on corneal endothelium after injection into the anterior chamber in a porcine eye model].
    Wilhelm A; Sietmann R; Wilhelm U; Hammer T
    Ophthalmologe; 2015 Apr; 112(4):346-52. PubMed ID: 25305043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).
    Stevenson W; Cheng SF; Dastjerdi MH; Ferrari G; Dana R
    Ocul Surf; 2012 Apr; 10(2):67-83. PubMed ID: 22482468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
    Kim EK; Kong SJ; Chung SK
    Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts.
    Kim EK; Kang SW; Kim JY; Min K; Kim TI
    Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3922-31. PubMed ID: 23640039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of intracameral injection of ranibizumab and bevacizumab on the corneal endothelium by scanning electron microscopy.
    Ari S; Nergiz Y; Aksit I; Sahin A; Cingu K; Caca I
    J Ocul Pharmacol Ther; 2015 Mar; 31(2):100-5. PubMed ID: 25574702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema.
    Guzel H; Bakbak B; Koylu MT; Gonul S; Ozturk B; Gedik S
    Cutan Ocul Toxicol; 2017 Mar; 36(1):5-8. PubMed ID: 26911396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA; Kim SJ
    Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
    Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
    Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of bevacizumab on cultured human corneal cells.
    Yoeruek E; Spitzer MS; Tatar O; Aisenbrey S; Bartz-Schmidt KU; Szurman P
    Cornea; 2007 Sep; 26(8):977-82. PubMed ID: 17721300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
    Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
    Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
    Kang S; Choi H; Rho CR
    J Ocul Pharmacol Ther; 2016 Dec; 32(10):671-676. PubMed ID: 27827554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
    Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
    Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
    Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
    J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.
    Al-Debasi T; Al-Bekairy A; Al-Katheri A; Al Harbi S; Mansour M
    Saudi J Ophthalmol; 2017; 31(2):99-105. PubMed ID: 28559722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
    Barzelay A; Lowenstein A; George J; Barak A
    Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.